Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 2/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301264 | 0.82 | MAPT (0.52) | NOTUMMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL15760357 | 0.82 | NOTUM (0.48) | NOTUMMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL31753907 | 0.80 | MAPT (0.49) | NOTUMMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL3529890 | 0.80 | SMN1; SMN2 (0.57) | MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL15753929 | 0.79 | TP53 (0.61) | NOTUMMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL15754705 | 0.79 | MAPT (0.44) | NOTUMMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL31301332 | 0.78 | MAPT (0.55) | NOTUMMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL31301291 | 0.78 | MAPT (0.45) | NOTUMMAPTTP53SMN1; SMN2POLB | |
| SCHEMBL13659759 | 0.77 | NOTUM (0.50) | NOTUMMAPTSMN1; SMN2POLBESRRA | |
| SCHEMBL31301479 | 0.76 | NOTUM (0.39) | NOTUMMAPTTP53SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | NOTUM 3845/4885MAPT 4575/4885TP53 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.